CN101977929B - 用于治疗变态反应的主要1类和2类螨变应原的低变应原性杂合蛋白 - Google Patents

用于治疗变态反应的主要1类和2类螨变应原的低变应原性杂合蛋白 Download PDF

Info

Publication number
CN101977929B
CN101977929B CN200980110215.6A CN200980110215A CN101977929B CN 101977929 B CN101977929 B CN 101977929B CN 200980110215 A CN200980110215 A CN 200980110215A CN 101977929 B CN101977929 B CN 101977929B
Authority
CN
China
Prior art keywords
der
ige
mite
protein
allergic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980110215.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN101977929A (zh
Inventor
安德烈斯·阿斯图里亚斯 奥特加 胡安
胡安安德烈斯·阿斯图里亚斯奥特加
洛佩兹 德 达瓦里洛 伊纳吉·伊巴罗拉
伊纳吉·伊巴罗拉洛佩兹德达瓦里洛
卡门·阿瑞拉 罗德里格斯 玛利亚
玛利亚卡门·阿瑞拉罗德里格斯
葛雷特 阿尔贝托·马丁尼兹
阿尔贝托·马丁尼兹葛雷特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roxall Medicina Espana SA
Original Assignee
Bial Industrial Farmaceutica SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial Industrial Farmaceutica SA filed Critical Bial Industrial Farmaceutica SA
Priority to CN201610835971.7A priority Critical patent/CN107118265A/zh
Publication of CN101977929A publication Critical patent/CN101977929A/zh
Application granted granted Critical
Publication of CN101977929B publication Critical patent/CN101977929B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Insects & Arthropods (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN200980110215.6A 2008-03-25 2009-03-24 用于治疗变态反应的主要1类和2类螨变应原的低变应原性杂合蛋白 Expired - Fee Related CN101977929B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610835971.7A CN107118265A (zh) 2008-03-25 2009-03-24 用于治疗变态反应的低变应原性杂合蛋白

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200800827 2008-03-25
ES200800827 2008-03-25
PCT/IB2009/005114 WO2009118642A2 (en) 2008-03-25 2009-03-24 Hypoallergenic hybrid proteins of major group 1 and 2 mite allergens for use in the treatment of allergies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610835971.7A Division CN107118265A (zh) 2008-03-25 2009-03-24 用于治疗变态反应的低变应原性杂合蛋白

Publications (2)

Publication Number Publication Date
CN101977929A CN101977929A (zh) 2011-02-16
CN101977929B true CN101977929B (zh) 2016-10-19

Family

ID=41110539

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200980110215.6A Expired - Fee Related CN101977929B (zh) 2008-03-25 2009-03-24 用于治疗变态反应的主要1类和2类螨变应原的低变应原性杂合蛋白
CN201610835971.7A Pending CN107118265A (zh) 2008-03-25 2009-03-24 用于治疗变态反应的低变应原性杂合蛋白

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610835971.7A Pending CN107118265A (zh) 2008-03-25 2009-03-24 用于治疗变态反应的低变应原性杂合蛋白

Country Status (9)

Country Link
US (2) US8951530B2 (enExample)
EP (3) EP2436691B1 (enExample)
JP (2) JP5793073B2 (enExample)
CN (2) CN101977929B (enExample)
BR (1) BRPI0908848A2 (enExample)
CA (1) CA2718994C (enExample)
ES (2) ES2638271T3 (enExample)
MX (1) MX2010010353A (enExample)
WO (1) WO2009118642A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011260233C1 (en) * 2010-06-03 2015-04-16 Alk-Abello A/S Pharmaceutical product comprising mite allergen extract(s) and a method for the manufacture thereof
EP2460824A1 (en) 2010-12-01 2012-06-06 Biomay Ag Hypoallergenic polypeptides for the treatment of house dust mite allergy
CN102676568A (zh) * 2012-05-08 2012-09-19 崔玉宝 一种生产重组粉尘螨变应原Der f1和Der f2融合蛋白的方法
EP2727934B1 (en) 2012-09-20 2016-06-15 Universidad de Cartagena Fusion proteins with representation of different allergens: vaccine proposal for mite allergies
US10457711B2 (en) * 2014-12-02 2019-10-29 Taiho Pharmaceutical Co., Ltd. Dermatophagoides farinae protein
NL2014882B1 (en) * 2015-05-29 2017-01-31 Citeq B V Allergy-specific immunotherapy compositions for use in the treatment of house-dust mite allergy.
AU2016333474A1 (en) * 2015-09-30 2018-03-22 Boehringer Ingelheim Vetmedica Gmbh Improved modular antigen transportation molecules and uses therof in animals
KR101858840B1 (ko) * 2016-01-15 2018-05-16 단국대학교 천안캠퍼스 산학협력단 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제
GB201602850D0 (en) * 2016-02-18 2016-04-06 Bial Ind Farmaceutica S A Fusion proteins
CN108265056B (zh) * 2016-12-31 2019-08-30 江苏众红生物工程创药研究院有限公司 一种重组户尘螨1类变应原蛋白及其制备方法和应用
CN109852652B (zh) * 2017-11-30 2023-05-02 江苏众红生物工程创药研究院有限公司 重组尘螨Ⅰ型变应原Der p1和Der f1蛋白的制备与应用
EP3569612A1 (en) 2018-05-18 2019-11-20 Biomay Ag Treatment and prevention of house dust mite allergies
CN113831400A (zh) * 2021-07-29 2021-12-24 沈阳医学院 一种尘螨致敏蛋白Der p 1的分离纯化方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070065468A1 (en) * 2005-08-29 2007-03-22 National University Of Singapore Chimeric allergens for immunotherapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0362290A4 (en) * 1987-06-17 1991-09-25 Princess Margaret Children's Medical Research Foundation (Inc.) Cloning of mite allergens
US5433948A (en) * 1990-02-13 1995-07-18 Thomas; Wayne R. Cloning and sequencing of allergens of dermatophagoides (house dust mite)
US7288256B1 (en) 1991-10-16 2007-10-30 Merck Patent Gmbh T cell epitopes of the major allergens from dermatophagoides (house dust mite)
GB9724531D0 (en) 1997-11-19 1998-01-21 Smithkline Biolog Novel compounds
EP1221317A1 (en) 2000-12-28 2002-07-10 SHAN-Beteiligungsgesellschaft m.b.H. Vaccines containing hybrid polypeptides consisting of at least two different allergenic proteins
FR2841906B1 (fr) 2002-07-05 2006-08-18 Stallergenes Sa Molecule d'acide nucleique codant une preproproteine d'allergene d'un acarien du genre dermatophagoides ou euroglyphus et son utilisation pour la production dudit allergene dans les plantes
ATE307141T1 (de) * 2003-01-21 2005-11-15 Biomay Prod & Handel Verfahren zur vorbereitung von hypoallergenen mosaikproteine
CN1780852A (zh) * 2003-04-25 2006-05-31 诺和酶股份有限公司 组1螨多肽变体
ITRM20040103A1 (it) 2004-02-27 2004-05-27 Consiglio Nazionale Ricerche Proteine di fusione comprendenti allergeni della famiglia delle ns-ltps, loro usi e composizioni farmaceutiche che le comprendono.
AT501101B1 (de) * 2004-12-02 2008-01-15 Biomay Ag Protein-allergen-derivat
CN100374152C (zh) * 2005-12-23 2008-03-12 中国农业大学 一种过敏性反应抑制剂
GB0607377D0 (en) 2006-04-12 2006-05-24 Glaxosmithkline Biolog Sa Novel Methods
EP1908777B1 (en) 2006-10-06 2016-02-03 Stallergenes Mite fusion proteins
EP1908776A1 (en) * 2006-10-06 2008-04-09 Stallergenes Sa Mite fusion proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070065468A1 (en) * 2005-08-29 2007-03-22 National University Of Singapore Chimeric allergens for immunotherapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Allergy multivaccines created by DNA shuffling of tree pollen allergens";WALLNER ET AL.;《JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY》;20070729;第120卷(第2期);374-380 *
"Biotechnology-based allergy diagnosis and vaccination";Prem L. Bhalla;《Trends in Biotechnology》;20080128;第26卷(第3期);153-161页 *

Also Published As

Publication number Publication date
BRPI0908848A2 (pt) 2015-12-01
JP2011517407A (ja) 2011-06-09
MX2010010353A (es) 2010-10-05
WO2009118642A2 (en) 2009-10-01
ES2638308T3 (es) 2017-10-19
EP2436691A2 (en) 2012-04-04
EP2436692A3 (en) 2012-06-27
US20110052640A1 (en) 2011-03-03
CA2718994A1 (en) 2009-10-01
EP2436692A2 (en) 2012-04-04
CN107118265A (zh) 2017-09-01
EP2436691A3 (en) 2012-06-27
US8951530B2 (en) 2015-02-10
ES2638271T3 (es) 2017-10-19
JP2015164424A (ja) 2015-09-17
WO2009118642A3 (en) 2009-12-03
JP5793073B2 (ja) 2015-10-14
CA2718994C (en) 2017-06-13
EP2436692B1 (en) 2017-08-02
JP6068544B2 (ja) 2017-01-25
US20150152148A1 (en) 2015-06-04
CN101977929A (zh) 2011-02-16
EP2268662A2 (en) 2011-01-05
EP2436691B1 (en) 2017-08-02

Similar Documents

Publication Publication Date Title
CN101977929B (zh) 用于治疗变态反应的主要1类和2类螨变应原的低变应原性杂合蛋白
US20210128719A1 (en) Modular antigen transportation molecules and uses thereof in animals
EP2646460B1 (en) Hypoallergenic polypeptides for the treatment of house dust mite allergy
US7696314B2 (en) Hypoallergenic mutant polypeptides based on fish parvalbumin
MX2008013050A (es) Proteinas quimericas hipoalergenicas pertenecientes a la familia de transportadoras de lipidos de parietaria judaica utiles para el tratamiento de alergias.
HK1168860A (en) Hypoallergenic hybrid proteins of major group 1 and 2 mite allergens for use in the treatment of allergies
HK1168861A (en) Hypoallergenic hybrid proteins of major group 1 and 2 mite allergens for use in the treatment of allergies
HK1168861B (en) Hypoallergenic hybrid proteins of major group 1 and 2 mite allergens for use in the treatment of allergies
US20140121356A1 (en) Hypoallergenic mutant polypeptides based on fish parvalbumin
HK1168860B (en) Hypoallergenic hybrid proteins of major group 1 and 2 mite allergens for use in the treatment of allergies
AU2011335007B2 (en) Hypoallergenic polypeptides for the treatment of house dust mite allergy
EA041116B1 (ru) Улучшенные транспортные молекулы модулярного антигена и их применение у животных

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: The Spanish

Applicant after: Bial Ind Farmaceutica S. A.

Address before: Bilbao

Applicant before: Bial Ind Farmaceutica S. A.

COR Change of bibliographic data
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20161019

Termination date: 20180324